In the latest trading session, CVS Health (CVS) closed at $77.9, marking a +1.51% move from the previous day.
CVS Health said on Thursday that its Aetna insurance business has over 81% of members in Medicare Advantage plans that are rated 4 stars or higher for 2026.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
CVS Health (CVS) reached $76.87 at the closing of the latest trading day, reflecting a +1.96% change compared to its last close.
CVS Health remains a solid, undervalued business, despite recent underperformance, versus the S&P 500 and ongoing margin pressures. Q2/25 results showed strong revenue growth but declining operating income and earnings, with updated guidance raising adjusted EPS expectations for 2025. Intrinsic value calculations suggest CVS Health is deeply undervalued, with a realistic fair value estimate of $135 per share, offering significant upside.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Healthcare investing has felt like walking through quicksand this year.
CVS Health (CVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CVS Health advances with Aetna margin recovery, digital investments and cost savings, making it the stronger healthcare bet over Elevance.
CVS Health's Q2 Health Services revenues climb 10%. Yet, AOI slips as cost pressures and Oak Street's rising MBR ail.
'Mad Money' host Jim Cramer takes a look at CVS and what is driving the stock up.